- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 1400KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 278KB)
Durvalumab – July 2019
Durvalumab (NSCLC): Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi™
Last updated
15 November 2019